

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company and potential investors with information on recent business developments of the Group.

The Group is a comprehensive pharmaceutical enterprise that has been operating in the healthcare sector for 30 years, with extensive management experience and a robust medical network. To adapt to changing market conditions and the widespread application of artificial intelligence in healthcare, the Board of Directors has prudently decided to transform the company into an AI-driven high-tech medical enterprise and has formulated a future development strategy.

The initial phase will focus on building a full-cycle intelligent healthcare ecosystem platform for bone health, encompassing “testing, treatment, and rehabilitation.”

PROGRESS ON THE BONE HEALTH “TESTING” BUSINESS

Reference is made to the announcements (the “**Announcements**”) of the Company dated 28 April 2025 and 29 April 2025 in relation to acquisition of 100% of the issued shares in the target companies to expand the artificial intelligence (AI) bone health diagnostics business and detection robots based on this. The Group is preparing a circular document for submission to the Stock Exchange for review, aiming to complete the acquisition as soon as possible.

PROGRESS ON THE BONE HEALTH “SMART HEALTHCARE” BUSINESS

In May 2025, the Group partnered with a Chinese state-owned company to launch the establishment of a Smart Healthcare Center, which will provide customized healthcare services to clients.

The Company has been actively exploring new opportunities and possibilities with an aim to promote return to its shareholders. Announcement(s) will be made on the Group's development in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (where applicable) as and when appropriate.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China NT Pharma Group Company Limited
NG TIT
Chairmen

Hong Kong, 30 July 2025

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng, Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.

This announcement contains forward-looking statements that reflect the Company's beliefs, plans or expectations about the future or future events. These statements are based on a number of assumptions, current estimates and projections, and are subject to risks, uncertainties and factors which may be beyond control. Actual outcomes may differ. These statements is not, and shall not be, relied upon as any assurance or representation as to the future or as a representation or warranty otherwise. Neither the Company nor its directors, officers, employees, agents, affiliates, advisers or representatives assume any responsibility to update these statements or to adapt them to future events or developments or to provide supplemental information in relation thereto or to correct any inaccuracies.